Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

David Brennan Appointed As Non-executive Director Of Reed Elsevier - Quick Facts

RELATED NEWS
Trade ENL now with 

Reed Elsevier Plc (ENL: Quote, REL.L) Thursday announced that Mr David Brennan has been appointed as a non-executive director of the company.

The company stated that David Brennan will assume office with effect from 1 November 2012, subject to shareholder approval at the respective Annual General Meetings to be held on 24 and 25 April 2012.

Mr Brennan is currently the Chief Executive Officer of AstraZeneca PLC, a global biopharmaceutical company, which develops, manufactures and markets prescription medicines.

Commenting on his appointment, Anthony Habgood, Chairman, said, "I would like to welcome David to Reed Elsevier. He has over 35 years experience in the biopharmaceutical industry and of the development, manufacture and commercialisation of innovative medicines. As a truly international executive with deep knowledge of the world's healthcare markets he will bring highly relevant experience to our board discussions….. '.

Click here to receive FREE breaking news email alerts for Reed Elsevier PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Colorado based doctor Dilip Joseph, who was kidnapped by the Taliban discusses his ordeal in detail in a book published by Amazon on Tuesday. Extending the rebound seen over the course of the previous session, stocks moved sharply higher during trading on Friday. The gains on the day partly offset the recent sell-off on Wall Street, although the major averages remain well off their mid-September highs. While the Ebola outbreak in the U.S. has thus far been limited to just three people, the results of a new CBS News poll suggest that news of the disease has contributed to a sharp drop in public confidence in the Centers for Disease Control and Prevention.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.